CA2567023C - Compositions and methods for bone formation and remodeling - Google Patents
Compositions and methods for bone formation and remodeling Download PDFInfo
- Publication number
- CA2567023C CA2567023C CA2567023A CA2567023A CA2567023C CA 2567023 C CA2567023 C CA 2567023C CA 2567023 A CA2567023 A CA 2567023A CA 2567023 A CA2567023 A CA 2567023A CA 2567023 C CA2567023 C CA 2567023C
- Authority
- CA
- Canada
- Prior art keywords
- wnt
- lrp5
- compound
- binding
- lrp6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 48
- 239000000203 mixture Substances 0.000 title claims description 40
- 230000011164 ossification Effects 0.000 title claims description 37
- 230000010072 bone remodeling Effects 0.000 title claims description 25
- 238000007634 remodeling Methods 0.000 title description 3
- 108050003627 Wnt Proteins 0.000 claims abstract description 123
- 102000013814 Wnt Human genes 0.000 claims abstract description 121
- 230000000694 effects Effects 0.000 claims abstract description 95
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 57
- 230000003993 interaction Effects 0.000 claims abstract description 50
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims abstract description 41
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims abstract description 41
- 101150021503 Mesd gene Proteins 0.000 claims abstract description 36
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims abstract description 21
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims abstract description 19
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 17
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 251
- 230000027455 binding Effects 0.000 claims description 169
- 230000005764 inhibitory process Effects 0.000 claims description 70
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims description 58
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims description 52
- 238000012216 screening Methods 0.000 claims description 35
- 230000006870 function Effects 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 22
- 230000007423 decrease Effects 0.000 claims description 20
- 238000003032 molecular docking Methods 0.000 claims description 17
- 239000005557 antagonist Substances 0.000 claims description 13
- 102000005698 Frizzled receptors Human genes 0.000 claims description 11
- 108010045438 Frizzled receptors Proteins 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 10
- 229930186217 Glycolipid Natural products 0.000 claims description 10
- 108090000288 Glycoproteins Proteins 0.000 claims description 10
- 102000003886 Glycoproteins Human genes 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 102000000470 PDZ domains Human genes 0.000 claims description 9
- 108050008994 PDZ domains Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 108010016283 TCF Transcription Factors Proteins 0.000 claims description 8
- 102000000479 TCF Transcription Factors Human genes 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 230000000638 stimulation Effects 0.000 claims description 8
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 claims description 7
- 102000052547 Wnt-1 Human genes 0.000 claims description 7
- 108700020987 Wnt-1 Proteins 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 208000020084 Bone disease Diseases 0.000 claims description 6
- 102000011087 DEP domains Human genes 0.000 claims description 6
- 108050001299 DEP domains Proteins 0.000 claims description 6
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 claims description 6
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 claims description 6
- 208000010392 Bone Fractures Diseases 0.000 claims description 5
- 206010061363 Skeletal injury Diseases 0.000 claims description 5
- 230000005856 abnormality Effects 0.000 claims description 5
- 239000004031 partial agonist Substances 0.000 claims description 5
- 230000026011 regulation of ossification Effects 0.000 claims description 5
- 102000016904 Armadillo Domain Proteins Human genes 0.000 claims description 4
- 108010014223 Armadillo Domain Proteins Proteins 0.000 claims description 4
- 241000289632 Dasypodidae Species 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000026749 regulation of bone remodeling Effects 0.000 claims description 4
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims description 3
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 claims description 3
- 102100037986 Dickkopf-related protein 4 Human genes 0.000 claims description 3
- 101710099554 Dickkopf-related protein 4 Proteins 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 108010006519 Molecular Chaperones Proteins 0.000 claims 7
- 102000005431 Molecular Chaperones Human genes 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 4
- 102000051172 Axin Human genes 0.000 claims 2
- 108700012045 Axin Proteins 0.000 claims 2
- 101100264044 Caenorhabditis elegans cwn-2 gene Proteins 0.000 claims 2
- 101100428953 Danio rerio wnt8a gene Proteins 0.000 claims 2
- 108091007911 GSKs Proteins 0.000 claims 2
- 101000650147 Gallus gallus Protein Wnt-9a Proteins 0.000 claims 2
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 2
- 101150019524 WNT2 gene Proteins 0.000 claims 2
- 102000052556 Wnt-2 Human genes 0.000 claims 2
- 108700020986 Wnt-2 Proteins 0.000 claims 2
- 102000043366 Wnt-5a Human genes 0.000 claims 2
- 108700020483 Wnt-5a Proteins 0.000 claims 2
- 101100485097 Xenopus laevis wnt11b gene Proteins 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 108090001093 Lymphoid enhancer-binding factor 1 Proteins 0.000 claims 1
- 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 113
- 230000035772 mutation Effects 0.000 abstract description 78
- 230000001404 mediated effect Effects 0.000 abstract description 56
- 230000011664 signaling Effects 0.000 abstract description 45
- 210000000963 osteoblast Anatomy 0.000 abstract description 23
- 230000008485 antagonism Effects 0.000 abstract description 16
- 230000003305 autocrine Effects 0.000 abstract description 9
- 230000003076 paracrine Effects 0.000 abstract description 8
- 210000004409 osteocyte Anatomy 0.000 abstract description 6
- 230000007246 mechanism Effects 0.000 abstract description 4
- 102200086054 rs121908668 Human genes 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 3
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 abstract description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
- 108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 description 157
- 102000001770 Low Density Lipoprotein Receptor-Related Protein-5 Human genes 0.000 description 155
- 230000014509 gene expression Effects 0.000 description 31
- 239000013612 plasmid Substances 0.000 description 27
- 238000003556 assay Methods 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 239000003636 conditioned culture medium Substances 0.000 description 22
- 238000003041 virtual screening Methods 0.000 description 20
- 239000005090 green fluorescent protein Substances 0.000 description 19
- 239000013613 expression plasmid Substances 0.000 description 18
- 101150002688 kremen1 gene Proteins 0.000 description 17
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 16
- 238000004166 bioassay Methods 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 13
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 108010015179 Low Density Lipoprotein Receptor-Related Protein-6 Proteins 0.000 description 10
- 102000001774 Low Density Lipoprotein Receptor-Related Protein-6 Human genes 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 238000000159 protein binding assay Methods 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004072 osteoblast differentiation Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000000853 LDL receptors Human genes 0.000 description 6
- 108010001831 LDL receptors Proteins 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000007781 signaling event Effects 0.000 description 5
- 102000017944 Dishevelled Human genes 0.000 description 4
- 108050007016 Dishevelled Proteins 0.000 description 4
- 102220494686 Small vasohibin-binding protein_R34E_mutation Human genes 0.000 description 4
- 238000005452 bending Methods 0.000 description 4
- 230000033558 biomineral tissue development Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000002924 energy minimization method Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002188 osteogenic effect Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 3
- 101710181403 Frizzled Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 102000002151 Microfilament Proteins Human genes 0.000 description 3
- 108010040897 Microfilament Proteins Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 108010008217 nidogen Proteins 0.000 description 3
- 201000001937 osteoporosis-pseudoglioma syndrome Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102220067600 rs777999570 Human genes 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 230000025487 vesicle localization Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000027587 GPCRs class F Human genes 0.000 description 2
- 108091008884 GPCRs class F Proteins 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- -1 LRP5ol71y Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000220259 Raphanus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000004156 Wnt signaling pathway Effects 0.000 description 2
- 101001124893 Xenopus laevis Nodal homolog 3-A Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002508 compound effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000001157 hypermorphic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 101150103084 siamois gene Proteins 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- AQSOTOUQTVJNMY-UHFFFAOYSA-N 7-(dimethylamino)-4-hydroxy-3-oxophenoxazin-10-ium-1-carboxylic acid;chloride Chemical compound [Cl-].OC(=O)C1=CC(=O)C(O)=C2OC3=CC(N(C)C)=CC=C3[NH+]=C21 AQSOTOUQTVJNMY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 101700047552 Axin-2 Proteins 0.000 description 1
- 102100035683 Axin-2 Human genes 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000012287 DNA Binding Assay Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 101710140933 Frizzled-8 Proteins 0.000 description 1
- 102100028466 Frizzled-8 Human genes 0.000 description 1
- 101000938351 Homo sapiens Ephrin type-A receptor 3 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101000972292 Mus musculus Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000000996 Secreted frizzled-related protein 3 Human genes 0.000 description 1
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 description 1
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000008758 canonical signaling Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000003674 cytoplasmic vesicle Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108010018632 frizzled related protein-3 Proteins 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000057382 human EPHA3 Human genes 0.000 description 1
- 102000055426 human LRP5 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002642 osteogeneic effect Effects 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001472 pulsed field gradient Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2772029A CA2772029C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771951A CA2771951C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771940A CA2771940C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2772033A CA2772033C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771941A CA2771941C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/849,067 US8637506B2 (en) | 2003-09-22 | 2004-05-19 | Compositions and methods for bone formation and remodeling |
| US10/849,067 | 2004-05-19 | ||
| PCT/US2005/017199 WO2005115354A2 (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
Related Child Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2771941A Division CA2771941C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771951A Division CA2771951C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771940A Division CA2771940C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2772033A Division CA2772033C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2772029A Division CA2772029C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2567023A1 CA2567023A1 (en) | 2005-12-08 |
| CA2567023C true CA2567023C (en) | 2012-07-03 |
Family
ID=35451375
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2771941A Expired - Lifetime CA2771941C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771951A Expired - Lifetime CA2771951C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771940A Expired - Lifetime CA2771940C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2772029A Expired - Lifetime CA2772029C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2772033A Expired - Lifetime CA2772033C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2567023A Expired - Lifetime CA2567023C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2771941A Expired - Lifetime CA2771941C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771951A Expired - Lifetime CA2771951C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2771940A Expired - Lifetime CA2771940C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2772029A Expired - Lifetime CA2772029C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
| CA2772033A Expired - Lifetime CA2772033C (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8637506B2 (enExample) |
| EP (3) | EP2409732B1 (enExample) |
| JP (1) | JP2008505190A (enExample) |
| CN (1) | CN101316627A (enExample) |
| CA (6) | CA2771941C (enExample) |
| IL (1) | IL179241A (enExample) |
| WO (1) | WO2005115354A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6780609B1 (en) * | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
| US6770461B1 (en) * | 1998-10-23 | 2004-08-03 | Genome Therapeutics Corporation | High bone mass gene of 11q13.3 |
| EP1483288A4 (en) * | 2001-05-11 | 2005-09-21 | Genome Therapeutics Corp | HBM VARIANTS MODULATING BONE MASS AND LIPID LEVELS |
| US20040221326A1 (en) * | 2001-05-11 | 2004-11-04 | Philip Babij | Transgenic animal model of bone mass modulation |
| US20030219793A1 (en) * | 2002-10-04 | 2003-11-27 | Carulli John P. | High bone mass gene of 11q13.3 |
| US7485460B2 (en) * | 2003-05-21 | 2009-02-03 | Tulane University Health Sciences Center | Enhanced growth of adult stem cells with Dkk-1 |
| US20120178697A9 (en) * | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
| US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US8367822B2 (en) * | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US20100041599A1 (en) | 2006-11-14 | 2010-02-18 | Dakai Liu | Compositions and methods for bone formation, bone remodeling and toxin protection |
| US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US9052324B2 (en) * | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| US8343922B2 (en) * | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| CA2685737A1 (en) * | 2007-04-30 | 2008-11-06 | Washington University | Methods and compositions for the treatment of cancer |
| WO2008144659A2 (en) * | 2007-05-18 | 2008-11-27 | Board Of Regents, The University Of Texas System | Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers |
| EP3305324A1 (en) * | 2007-11-02 | 2018-04-11 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
| WO2009064944A2 (en) * | 2007-11-16 | 2009-05-22 | Nuvelo, Inc. | Antibodies to lrp6 |
| US8716243B2 (en) * | 2008-05-28 | 2014-05-06 | St. Jude Childen's Research Hospital | Methods of effecting Wnt signaling through Dkk structural analysis |
| WO2010108001A2 (en) * | 2009-03-18 | 2010-09-23 | The Brigham And Women's Hospital, Inc. | Agents and methods for tissue repair and regeneration |
| NZ596274A (en) | 2009-05-12 | 2013-11-29 | Pfizer | Blocking anti-dkk-1 antibodies and their uses |
| EP2566892B1 (en) | 2010-05-06 | 2017-12-20 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| CA2798390A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| US11167011B2 (en) | 2010-06-07 | 2021-11-09 | Enzo Biochem, Inc. | Methods for treating bone loss using sclerostin peptides |
| US9617323B2 (en) | 2010-06-07 | 2017-04-11 | Joshua Rabbani | Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor |
| US9493541B2 (en) | 2010-06-07 | 2016-11-15 | Joshua Rabbani | Antibodies specific for sulfated sclerostin |
| US9403882B2 (en) | 2010-06-07 | 2016-08-02 | Joshua Rabbani | Sulfation of Wnt pathway proteins |
| BR112013017711A2 (pt) * | 2011-01-11 | 2016-08-23 | Fate Therapeutics Inc | novas composições de wnt e usos terapêuticos de tais composições |
| KR101303941B1 (ko) | 2011-03-31 | 2013-09-05 | 연세대학교 산학협력단 | 피마자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물 |
| EP3290442A1 (en) | 2011-11-04 | 2018-03-07 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs |
| CN103966229A (zh) * | 2014-05-09 | 2014-08-06 | 中山大学 | bbeAMP基因、其编码的蛋白质、以bbeAMP为目的基因生产的融合蛋白及其应用 |
| EP4219564A1 (en) | 2014-09-12 | 2023-08-02 | The Board of Trustees of the Leland Stanford Junior University | Wnt signaling agonist molecules |
| CN106367517A (zh) * | 2016-09-28 | 2017-02-01 | 湖北工业大学 | 一种低密度脂蛋白受体相关蛋白5基因突变检测的试剂及应用 |
| CA3085785A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-lrp5/6 antibodies and methods of use |
| CN117946267A (zh) | 2017-12-19 | 2024-04-30 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
| AU2018393073B2 (en) | 2017-12-19 | 2025-09-18 | Surrozen Operating, Inc. | Wnt surrogate molecules and uses thereof |
| CN111632147A (zh) * | 2020-06-07 | 2020-09-08 | 重庆医科大学 | 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用 |
| CN115309402B (zh) * | 2022-07-13 | 2023-10-24 | 国网江苏省电力有限公司信息通信分公司 | 一种可量化差异的异构执行程序集合构成方法及装置 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS562623A (en) * | 1979-06-21 | 1981-01-12 | Matsushita Electric Industrial Co Ltd | Electrode |
| DE69420649T2 (de) * | 1993-08-19 | 2000-05-04 | Advanced Micro Devices, Inc. | Voll differentieller Operationsverstärker mit niedriger Versorgungsspannung |
| US7244577B2 (en) | 1997-04-15 | 2007-07-17 | Merck & Co., Inc. | Method of screening for modulator of LRP5 activity |
| DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| AU3510200A (en) * | 1999-03-05 | 2000-09-21 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| CA2404658A1 (en) | 2000-03-29 | 2001-10-04 | Ismail Moarefi | 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides |
| US7713526B2 (en) * | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| EP1395285A4 (en) | 2001-05-17 | 2005-06-01 | Genome Therapeutics Corp | REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| US20040235728A1 (en) | 2001-11-08 | 2004-11-25 | Stoch Selwyn Aubrey | Compositions and methods for treating osteoporosis |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US20050084494A1 (en) | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
| US20120178697A9 (en) | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
| US9046537B2 (en) * | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8637506B2 (en) | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8343922B2 (en) | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
| US7838252B2 (en) | 2005-02-17 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating a subject having an anthrax toxin mediated condition |
-
2004
- 2004-05-19 US US10/849,067 patent/US8637506B2/en not_active Expired - Lifetime
-
2005
- 2005-05-18 CA CA2771941A patent/CA2771941C/en not_active Expired - Lifetime
- 2005-05-18 WO PCT/US2005/017199 patent/WO2005115354A2/en not_active Ceased
- 2005-05-18 CA CA2771951A patent/CA2771951C/en not_active Expired - Lifetime
- 2005-05-18 EP EP11184755.4A patent/EP2409732B1/en not_active Expired - Lifetime
- 2005-05-18 CA CA2771940A patent/CA2771940C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2772029A patent/CA2772029C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2772033A patent/CA2772033C/en not_active Expired - Lifetime
- 2005-05-18 CN CNA2005800243835A patent/CN101316627A/zh active Pending
- 2005-05-18 JP JP2007527363A patent/JP2008505190A/ja active Pending
- 2005-05-18 CA CA2567023A patent/CA2567023C/en not_active Expired - Lifetime
- 2005-05-18 EP EP05751764A patent/EP1758562B1/en not_active Expired - Lifetime
- 2005-05-18 EP EP16000780.3A patent/EP3150255A1/en not_active Withdrawn
-
2006
- 2006-11-13 IL IL179241A patent/IL179241A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20050196349A1 (en) | 2005-09-08 |
| CA2771940C (en) | 2016-01-12 |
| CA2771941C (en) | 2015-03-31 |
| WO2005115354A3 (en) | 2007-09-13 |
| JP2008505190A (ja) | 2008-02-21 |
| CA2771940A1 (en) | 2005-12-08 |
| CA2772033C (en) | 2016-05-17 |
| EP1758562A2 (en) | 2007-03-07 |
| EP1758562B1 (en) | 2012-12-05 |
| CN101316627A (zh) | 2008-12-03 |
| IL179241A0 (en) | 2007-03-08 |
| EP1758562A4 (en) | 2009-07-22 |
| US8637506B2 (en) | 2014-01-28 |
| EP2409732A1 (en) | 2012-01-25 |
| CA2771951C (en) | 2014-07-08 |
| IL179241A (en) | 2016-04-21 |
| CA2772033A1 (en) | 2005-12-08 |
| CA2772029A1 (en) | 2005-12-08 |
| EP2409732B1 (en) | 2016-04-06 |
| CA2771941A1 (en) | 2005-12-08 |
| US20060198791A2 (en) | 2006-09-07 |
| CA2771951A1 (en) | 2005-12-08 |
| EP3150255A1 (en) | 2017-04-05 |
| CA2772029C (en) | 2016-05-17 |
| WO2005115354A2 (en) | 2005-12-08 |
| CA2567023A1 (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2567023C (en) | Compositions and methods for bone formation and remodeling | |
| JP4993623B2 (ja) | スクレロスチンおよびＷｎｔシグナル伝達ならびに骨形成の阻止阻害 | |
| Zhang et al. | The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd | |
| Li et al. | Activation of FAK and Src are receptor-proximal events required for netrin signaling | |
| Gong et al. | LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development | |
| Li et al. | PLC-γ1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration | |
| Cong et al. | Casein kinase Iε modulates the signaling specificities of dishevelled | |
| JP6255156B2 (ja) | チロシンキナーゼ受容体由来の細胞外アロステリック阻害剤結合ドメイン | |
| US8716243B2 (en) | Methods of effecting Wnt signaling through Dkk structural analysis | |
| HK1150962A (en) | Sclerostin and the inhibition of wnt signaling and bone formation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |